JPS6157828B2 - - Google Patents
Info
- Publication number
- JPS6157828B2 JPS6157828B2 JP952279A JP952279A JPS6157828B2 JP S6157828 B2 JPS6157828 B2 JP S6157828B2 JP 952279 A JP952279 A JP 952279A JP 952279 A JP952279 A JP 952279A JP S6157828 B2 JPS6157828 B2 JP S6157828B2
- Authority
- JP
- Japan
- Prior art keywords
- present
- formula
- compound
- administered
- represented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 15
- -1 nicotinoyl group Chemical group 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 description 3
- 229960000903 pantethine Drugs 0.000 description 3
- 235000008975 pantethine Nutrition 0.000 description 3
- 239000011581 pantethine Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000003307 slaughter Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 238000000434 field desorption mass spectrometry Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
Landscapes
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP952279A JPS55102566A (en) | 1979-01-30 | 1979-01-30 | Nicotinoylpantethine derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP952279A JPS55102566A (en) | 1979-01-30 | 1979-01-30 | Nicotinoylpantethine derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS55102566A JPS55102566A (en) | 1980-08-05 |
| JPS6157828B2 true JPS6157828B2 (US20110232667A1-20110929-C00004.png) | 1986-12-09 |
Family
ID=11722591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP952279A Granted JPS55102566A (en) | 1979-01-30 | 1979-01-30 | Nicotinoylpantethine derivative |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS55102566A (US20110232667A1-20110929-C00004.png) |
-
1979
- 1979-01-30 JP JP952279A patent/JPS55102566A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS55102566A (en) | 1980-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH07502265A (ja) | 酸化窒素供与体プロドラッグとしての求核試薬−酸化窒素付加物の酸素置換誘導体 | |
| JPS58177953A (ja) | ポリプレニルカルボン酸アミドおよびその製造方法 | |
| Hosoda et al. | Convenient, high yield conversion of androst-5-ene-3. beta., 17. beta.-diol to dehydroisoandrosterone | |
| JPH0370698B2 (US20110232667A1-20110929-C00004.png) | ||
| JPS6246554B2 (US20110232667A1-20110929-C00004.png) | ||
| JPS6157828B2 (US20110232667A1-20110929-C00004.png) | ||
| US5061711A (en) | Method of curing liver diseases by using pyrrolo quinoline quinone triesters and novel pyrrolo quinoline quinone triesters | |
| JPH0243749B2 (US20110232667A1-20110929-C00004.png) | ||
| JPS63295561A (ja) | ２−キノロン誘導体 | |
| JPS6330283B2 (US20110232667A1-20110929-C00004.png) | ||
| JPS6056130B2 (ja) | 新規なサリチル酸誘導体 | |
| US4024280A (en) | Abietanilides, their production and use | |
| JPS6151585B2 (US20110232667A1-20110929-C00004.png) | ||
| JPS6183163A (ja) | 抗腫瘍剤 | |
| JPH0370700B2 (US20110232667A1-20110929-C00004.png) | ||
| JP2020528067A (ja) | ステロイド系誘導体ｆｘｒアゴニストの結晶又は非晶質、その製造方法及び使用 | |
| JPH01249733A (ja) | ペンタン二酸誘導体の代謝物質 | |
| US2296167A (en) | Acyl derivatives of vitamin b6 and process of making the same | |
| CA2037092C (en) | Bile acid unsaturated derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | |
| JPH04290846A (ja) | トリテルペノイド化合物およびその用途 | |
| EP3889149A1 (en) | Solid form, crystalline form, and crystal form a of fxr agonist, and preparation method therefor and application thereof | |
| JPH0725771B2 (ja) | ２−アミノエタンスルホン酸亜鉛錯化合物 | |
| JPS6144853A (ja) | γ−リノレン酸誘導体およびこれを含有する血小板凝集抑制剤 | |
| JPS5892699A (ja) | ３′′′−デヒドロ−カルデノリド−トリジギトキソシド−オキシム、その製法及び該化合物を含有する心不全用治療薬 | |
| RU2015964C1 (ru) | Способ получения замещенных производных амина |
